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Abstract: Turmeric, a popular ingredient in the cuisine of many Asian countries, comes from the roots
of the Curcuma longa and is known for its use in Chinese and Ayurvedic medicine. Turmeric is rich in
curcuminoids, including curcumin, demethoxycurcumin, and bisdemethoxycurcumin. Curcuminoids
have potent wound healing, anti-inflammatory, and anti-carcinogenic activities. While curcuminoids
have been studied for many years, not much is known about their effects on steroid metabolism.
Since many anti-cancer drugs target enzymes from the steroidogenic pathway, we tested the effect of
curcuminoids on cytochrome P450 CYP17A1, CYP21A2, and CYP19A1 enzyme activities. When using
10 µg/mL of curcuminoids, both the 17α-hydroxylase as well as 17,20 lyase activities of CYP17A1
were reduced significantly. On the other hand, only a mild reduction in CYP21A2 activity was
observed. Furthermore, CYP19A1 activity was also reduced up to ~20% of control when using
1–100 µg/mL of curcuminoids in a dose-dependent manner. Molecular docking studies confirmed that
curcumin could dock onto the active sites of CYP17A1, CYP19A1, as well as CYP21A2. In CYP17A1
and CYP19A1, curcumin docked within 2.5 Å of central heme while in CYP21A2 the distance from
heme was 3.4 Å, which is still in the same range or lower than distances of bound steroid substrates.
These studies suggest that curcuminoids may cause inhibition of steroid metabolism, especially at
higher dosages. Also, the recent popularity of turmeric powder as a dilatory supplement needs
further evaluation for the effect of curcuminoids on steroid metabolism. The molecular structure
of curcuminoids could be modified to generate better lead compounds with inhibitory effects on
CYP17A1 and CYP19A1 for potential drugs against prostate cancer and breast cancer.
Keywords: curcumin; curcuminoid; diferuloylmethane; E100; CYP19A1; aromatase; estrogen
synthase; cytochrome P450
1. Introduction
Turmeric, the well-known yellow spice and coloring agent, is found in the cuisine of numerous
Asian countries. Turmeric is also recognized for its use in Chinese and Ayurvedic medicine and has been
tested for anti-microbial activity as far back as 1949 [1,2]. Turmeric is produced commercially from the
dried rhizomes of the plant Curcuma longa, which belongs to the ginger family Zingiberaceae. Curcumin
(CI-75300, diferuloylmethane, E100, Natural Yellow 3) is the most abundant of the curcuminoids and
enhances wound healing, modulates angiogenesis and the immune system, and has anti-inflammatory,
anti-oxidant, anti-infective and anti-cancer activities [3]. Since the discovery of curcumin as a bioactive
compound, many biological activities have been described [4]. Curcumin has been shown to modulate
molecular signaling pathways, such as the aryl hydrocarbon receptor, the induction of Nuclear factor
erythroid 2-related factor 2 (Nrf2) or the inhibition of nuclear factor kappa-light-chain-enhancer of
activated B cells (NF-κB), initiating the activation of inflammatory and immunogenic factors. Curcumin
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can also inhibit angiogenesis and induce apoptosis on cancerous cells [5,6]. Curcumin is also involved
in the increase of insulin in plasma and the decrease of blood glucose in diabetic patients [7,8].
Several investigators have studied the effect of curcumin in prostate cancer [9]. Chendil et al.
showed that curcumin treatment of prostate cancer cell line PC-3 in combination with radiation
inhibited tumor necrosis factor (TNF)-alpha-mediated NF-κB activity resulting in B-cell lymphoma
2 (bcl-2) protein downregulation [10]. Curcumin has been shown to downregulate the androgen
receptor in prostate cancer cells [11]. Several curcumin analogues have been made and tested in
prostate cancer cells and many compounds with cytotoxicity toward prostate cancer cell lines have
been identified in these studies [12–18]. Curcumin was also found to exhibit a protective effect
against natural and chemical toxicities [19]. Structurally, curcumin has two aryl moieties connected
by a seven-carbon chain. By varying the motifs from the primary structure, synthetic molecules can
be created and a liposomal curcumin preparation can also be prepared for improved stability and
bioavailability [20–22]. A more recent approach to improve bioavailability of curcumin has been to use
nano formulations of curcumin [23–25]. Several different nanocurcumin preparations have been made
and tested for in vitro as well as in vivo effects and toxicities [26–28]. The nano particle formulations
of curcumin have been shown to improve bioavailability and therapeutic potential of curcumin and its
analogues and can be considered a medium of choice for delivery of curcuminoids [29–33].
Anti-cancer activity of curcumin was first described by Kuttan et al. in 1985 [34].
Since then, different research groups have been testing curcumin in vitro, and several clinical
trials have been carried out to test the biological activities of curcumin preparations [35].
The curcumin molecule itself has poor solubility in water, and therefore, often shows low
bioavailability when consumed directly [20,36]. Different methods have been developed to increase
curcumin bioavailability, and in it has been shown that combining curcumin with piperine
((2E,4E)-5-(2H-1,3-Benzodioxol-5-yl)-1-(piperidin-1-yl)penta-2,4-dien-1-one), a component of black
pepper obtained fromPiper nigrum, the bioavailability of curcumin was increased significantly [20,22,37].
Most of the hormonal-dependent cancers, such as breast and prostate cancer, are treated by blocking
the synthesis of estrogens and androgens [38], by targeting enzymes from the steroidogenesis pathway
(Figure 1). The CYP17A1 enzyme (GeneID: 1586, 10q24.32, GRCh38 chr10:102,830,531-102,837,533,
NCBI: NM_000102.4, NP_000093.1, OMIM: 609300) regulates sex steroid biosynthesis in humans
through 17α-hydroxylase/17,20 lyase activities and is a target of the anti-prostate cancer drug
abiraterone [39–41]. Aromatase (CYP19A1) converts androstenedione and testosterone into estrogens
and is a target for the treatment of breast cancer [42–44]. The CYP19A1 protein contains 503 amino acids
(NP_000094) and is encoded by the CYP19A1 gene (GeneID:1588, NCBI: NM_000103, 15q21.2, GRCh38
15:51208056-51338597). The cytochrome P450 21-hydroxylase, coded by CYP21A2 (GeneID: 1589,
NCBI: NM_000500.9, NP_000491.4, 6p21.33, GRCh38 chr6:32,038,265-32,041,670, OMIM: 613815) is
needed for biosynthesis of mineralocorticoids and glucocorticoids. In the adrenals, CYP21A2 converts
progesterone into 11-deoxycorticosterone and 17α-hydroxyprogesterone into 11-deoxycortisol [39].
All these cytochromes P450, the CYP17A1, CYP19A1, and CYP21A2 are membrane-bound proteins
and belong to the cytochrome P450 protein superfamily. Cytochromes P450 enzymes are involved in
the biotransformation of drugs, xenobiotics, and steroid hormones [45]. There are different types of
cytochrome P450 proteins in humans. The cytochrome P450 proteins located inside the mitochondrion
metabolize steroids and sterols in partnership with ferredoxin and ferredoxin reductase and are called
type 1 cytochrome P450 [46]. The majority of cytochrome P450 proteins in humans (50 out of 57) are
located in the smooth endoplasmic reticulum and depend on cytochrome P450 oxidoreductase [47]
as their redox partner (type 2 cytochrome P450). The microsomal P450 enzymes metabolize drugs,
xenobiotics as well as endogenous substrates, including many steroid hormones like pregnenolone,
17α-hydroxypregnenolone, dehydroepiandrosterone, testosterone, and androstenedione [39,47].
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Figure 1. Synthesis of steroid hormones in humans. After entering the mitochondrion, cholesterol is 
converted into pregnenolone, which is used as a substrate by CYP17A1 in the endoplasmic reticulum 
to produce sex steroids. First, the cholesterol is converted into pregnenolone by the enzyme CYP11A1 
(P450scc) inside the mitochondria. Pregnenolone is converted into progesterone by HSD3B2 and into 
17OH-pregnenolone by the 17α-hydroxylase activity of CYP17A1. Progesterone is converted into 
deoxycorticosterone by CYP21A2 and into 17OH-progesterone by the 17α-hydroxylase activity of 
CYP17A1. The 17,20 lyase activity of human CYP17A1 converts 17OH-pregnenolone into DHEA but 
has poor specificity for 17OH-progesterone as a substrate. The 17OH-progesterone is converted into 
11-DOC by the 21-hydroxylase activity of CYP21A2. The CYP19A1 (aromatase) converts androgens 
into estrogens and uses androstenedione as its major substrate. The 5α-reductase, SRD5A2, converts 
testosterone into dihydrotestosterone. Abbreviations: Preg = pregnenolone, Prog = progesterone, 
DOC = deoxycorticosterone, 11DOC = 11-deoxycortisol, DHEA = dehydroepiandrosterone, HSD3B2 
= 3β-hydroxysteroid dehydrogenase type 2, HSD17B1/2 = 17β-hydroxysteroid dehydrogenase type 
1/2, SRD5A2 = 5α-reductase type 2. 
Curcumin, demethoxycurcumin, and bisdemethoxycurcumin are the most abundant 
components of turmeric; together, these are called curcuminoids (Figure 2). While activities of 
curcuminoids have been tested against a wide range of metabolic targets, not much is known about 
the effect of curcuminoids on the steroid metabolism in humans. Considering the widespread use of 
turmeric powder, which is rich in curcuminoids, we sought to examine the effects of curcuminoids 
extracted from C. longa on the metabolism of steroid hormones. Here we report that curcuminoids 
may inhibit the biosynthesis of steroid hormones. We tested the effect of curcuminoids at different 
dosages on the activities of steroid-metabolizing enzymes, CYP17A1 and CYP21A2, using adrenal 
carcinoma cell line NCI-H295R and the endoplasmic reticulum from the placental carcinoma cell line 
Figure 1. Synthesis of steroid hormones in humans. After entering the mitochondrion, cholesterol is
converted into pregnenolone, which is used as a substrate by CYP17A1 in the endoplasmic reticulum
to produce sex steroids. First, the cholesterol is converted into pregnenolone by the enzyme CYP11A1
(P450scc) inside the mitochondria. Pregnenolone is converted into progesterone by HSD3B2 and into
17OH-pregnenolone by the 17α-hydroxylase activity of CYP17A1. Progesterone is converted into
deoxycorticosterone by CYP21A2 and into 17OH-progesterone by the 17α-hydroxylase activity of
CYP17A1. The 17,20 lyase activity of human CYP17A1 converts 17OH-pregnenolone into DHEA but
has poor specificity for 17OH-progesterone as a substrate. The 17OH-progesterone is converted into
11-DOC by the 21-hydroxylase activity of CYP21A2. The CYP19A1 (aromatase) converts androgens
into estrogens and uses androstenedione as its major substrate. The 5α-reductase, SRD5A2, converts
testosterone into dihydrotestosterone. Abbreviations: Preg = pregnenolone, Prog = progesterone,
DOC = deoxycorticosterone, 11DOC = 11-deoxycortisol, DHEA = dehydroepiandrosterone, HSD3B2 =
3β-hydroxysteroid dehydrogenase type 2, HSD17B1/2 = 17β-hydroxysteroid dehydrogenase type 1/2,
SRD5A2 = 5α-reductase type 2.
Curcumin, demethoxycurcumin, and bisdemethoxycurcumin are the most abundant components
of turmeric; together, these are called curcuminoids (Figure 2). While activities of curcuminoids
have been tested against a wide range of metabolic targets, not much is known about the effect of
curcuminoids on the steroid metabolism in humans. Considering the widespread use of turmeric
powder, which is rich in curcuminoids, we sought to examine the effects of curcuminoids extracted
from C. longa on the metabolism of steroid hormones. Here we report that curcuminoids may inhibit
the biosynthesis of steroid hormones. We tested the effect of curcuminoids at different dosages on
the activities of steroid-metabolizing enzymes, CYP17A1 and CYP21A2, using adrenal carcinoma
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cell line NCI-H295R and the endoplasmic reticulum from the placental carcinoma cell line JEG3 was
used for CYP19A1 activity. Inhibition of CYP17A1 and CYP19A1 activities by curcuminoids indicate
similar molecular entities or modified compounds based on core structures of curcuminoids could be
explored as potential treatments for prostate cancer by targeting CYP17A1 and for breast cancer by
targeting CYP19A1.
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composition of our turmeric extract was checked by thin-layer chromatography using 
chloroform:hexane:methanol (1:1:0.1, v/v/v) as the mobile phase. Curcuminoids in our turmeric 
extract were identified as curcumin (69.7%), bisdemethoxycurcumin (25.8%), and 
demethoxycurcumin (4.5%) and curcumin was the major component as has been shown in previous 
publications describing curcuminoid content of C. longa [48]. 
2. Results 
2.1. Isolation of Curcuminoids from Turmeric Powder and Characterization 
We used dried turmeric powder to obtain the curcuminoid preparation used in our experiments. 
An initial extraction in ethanol was carried out to dissolve the curcuminoids, and then curcuminoids 
were separated by filtration. Ethanolic extract was dried under nitrogen and then extracted with 
hexane to remove bound impurities as curcuminoids are not soluble in hexane. After two rounds of 
hexane extraction, curcuminoids were crystallized in a 50:50 mix of hexane and propanol and then 
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curcuminoids present in our preparation, a thin-layer chromatographic separation was carried out as 
described previously. Our curcuminoid preparation indicated the presence of curcumin as the major 
Figure 2. he ical structure of curcu inoids, and characterization of curcu inoids extracted fro
tur eric used in this study. The ain co ponents of tur eric are curcu in, des ethoxycurcu in,
and bis-desmethoxycurcumin. Curcuminoids were obtained from the dried turmeric powder
(from Curcuma longa) by solvent extraction using ethanol and purified further by selective
extraction and crystallization using hexane and isopropanol as described in the methods section.
Curcuminoid composition of our turmeric extract was checked by thin-layer chromatography using
chloroform:hexane:methanol (1:1:0.1, v/v/v) as the mobile phase. Curcuminoids in our turmeric extract
were identified as curcumin (69.7%), bisdemethoxycurcumin (25.8%), and demethoxycurcumin (4.5%)
and curcumin was the major component as has been shown in previous publications describing
curcuminoid content of C. longa [48].
2. Results
2.1. Isolation of Curcuminoids from Turmeric Powder and Characterization
We used dried turmeric powder to obtain the curcuminoid preparation used in our experiments.
An initial extraction in ethanol as carried out to dissolve the curcuminoids, and then curcuminoids
were separated by filtration. Ethanolic extract was dried under nitrogen and then extracted with
hexane to remove bound impurities as curcuminoids are not soluble in hexane. After two rounds of
hexane extraction, curcuminoids were crystallized in a 50:50 mix of hexane and propanol and then
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dried. A stock solution of curcuminoids was made in ethanol. For the determination of the nature of
curcuminoids present in our preparation, a thin-layer chromatographic separation was carried out as
described previously. Our curcuminoid preparation indicated the presence of curcumin as the major
curcuminoid (69.7%) and demethoxycurcumin (4.5%)/bisdemethoxycurcumin (25.8%) were present as
minor components (Figure 2), which is similar to previous reports describing curcuminoid separation
from the powders ofC. longa. We performed a UV–Vis spectrum analysis of our curcuminoid preparation
and saw an absorption maximum at 427 nm in ethanol (Figure 3A), which was in agreement with values
reported previously [49,50]. Further analysis with fluorescence spectroscopy indicated an emission
maximum between 532–538 nm (Figure 3B). Using the known molar extinction coefficient values of
purified curcumin (ε=61.864 cm−1 mM−1), we calculated the total amount of curcuminoids present
in our preparation and observed that estimated values were in agreement with the experimentally
determined results, indicating high purity of our curcuminoid preparation (Table 1).
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extinction coefficient of 61.864 cm−1 mM−1 for pure curcumin (Table 1). (B) Fluorescence spectra of 
increasing concentrations (1.25–20 µM) of curcuminoid preparation were used in our studies. First, 
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Figure 3. Spectral analysis of curcuminoid preparation used in our studies. (A) UV–Vis spectra of
curcuminoid preparations. Curcuminoids were dissolved in ethanol and spectra were recorded on
a SpectraMax M2e spectrophotometer between 350–550 nm. Different concentrations of the curcuminoid
extract (1.25–20 µM) were used for recording the spectra. An absorption maximum of 427 nm was
observed for our curcuminoid preparation. Based on absorption values obtained from our preparation,
an estimation of curcuminoid concentration was performed using a millimolar extinction coefficient of
61.864 cm−1 mM−1 for pure curcumin (Table 1). (B) Fluorescence spectra of increasing concentrations
(1.25–20 µM) of curcuminoid preparation were used in our studies. First, an initial scan of excitation
wavelength was performed, then in the emission scans, the excitation wavelength was fixed at 425 nm.
A smooth emission maximum between 532–538 nm was observed for our curcuminoid preparation.
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Table 1. Calculation of curcuminoid concentration based on spectral analysis. Different concentrations
of our curcuminoid preparation were analyzed in a SpectraMax M2e spectrophotometer in a volume of
200 µL (pathlength 0.56 cm). The calculated values were in good agreement with the estimated values,
indicating a high degree of purity in our curcuminoid preparation.






2.2. Toxicity of Curcuminoids on NCI-H295R Cells
We first determined the toxicity of the curcuminoids towards the steroid metabolizing NCI-H295R
adrenal cancer cell line, which was then used in subsequent experiments (Figure 4). A range of
curcuminoid concentrations were tested with NCI-H295R cells to determine the maximum concentration
of curcuminoid preparation that was not toxic for the cells. We observed that at 50 µg/mL or higher
concentrations of curcuminoid preparation, only 25% of the NCI-H295R cells survived, while at
25 µg/mL or lower concentrations of curcuminoids, most of the cells were found to be viable.
We did not observe cell death between 0.78–12.5 µg/mL of curcuminoid preparation, and a standard
concentration of 10 µg/mL curcuminoid preparation was used in further experiments. Similarly, the
toxicity of curcuminoid preparation was also tested for HEK-293 cells, and no significant toxicity
was observed below 6.25 µg/mL or higher concentrations. These results are in agreement with the
previously reported toxicity values for curcumin in NIH3T3, H9C2, and HepG2 cells [51]. Human trials
using up to 8000 mg of curcumin found no evidence of toxicity [52].
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Figure 4. Measurement of cytotoxicity of curcu inoid preparation. Effect of curcuminoids on
cytotoxicity and viability of human adrenal I- 295 cells was determined using a range of
cur minoid con e trations between 0.78–100µg/mL over 24 h as de cribed in methods. The NCI-H295R
cells were grown overnight and t en treated wi h varying co centrations f curc mino ds for 24 h.
After t e incubatio with curcuminoids, culture medi m was re oved, and c ll viability was de ermined
by 3-(4,5-dimeth lthiazol-2-yl)-2,5-d phenyltetrazolium bromide (MTT) reduction assay. No significant
effect on the v ab l ty of NCI-H295R cells was observed at 25 µg/mL r low r doses of curcuminoids.
In subsequent experiments, the conc tration of curcumin ids w s kept below 10 µg/mL. Data are
presented as the ean and standard deviation of three independent replicates. The test for statistical
significance was done between each sample with the control (Ctrl) by one-way ANOVA groups marked
as * p < 0.05; ** p < 0.001 confirmed significant changes.
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2.3. Bioactivity of Curcuminoids on Steroid Biosynthesis
We tested the bioactivity of our curcuminoid preparation of steroid production by human
adrenal NCI-H295R cells [53]. A primary cell line model representing adrenals is not available.
The NCI-H295 cells have been shown to express the enzymes involved in the biosynthesis of steroids
in human adrenals and therefore, the NCI-H295R cells have been an excellent model to study the
molecular mechanisms of steroid regulation and human adrenal steroidogenesis [54,55]. To test
the effects of curcuminoids on adrenal steroid production, we treated the NCI-H295R cells with
10 µg/mL of curcuminoid preparation and used pregnenolone as a substrate. We compared the effect
of curcuminoids on steroid biosynthesis in NCI-H295R cells with abiraterone, a known inhibitor of
CYP17A1 and CYP21A2 activities. The curcuminoids, as well as abiraterone, blocked the production
of 17α-hydroxypregnenolone and dehydroepiandrosterone (DHEA), indicating inhibition of CYP17A1
activities (Figure 5).
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Figure 5. Effect of curcuminoids on steroid production. A representative thin layer chromatogram
is shown illus rating the effect on steroid production by th NCI-H295R cells from t e curcuminoids
extracted from turmeric. Human adrenal NCI-H295R cells were incubated wit tritium labeled
pregn nolone and then treated with curcuminoids and abiraterone, a known inhibitor of CYP17A1.
After i cubatio s, steroids were extracted by rganic solvents, dried u der nitrogen and separated
by thi layer chromatography (TLC). Radioactivity containe in steroids was visualized using
autoradiography on a phosphorimager and quantitated by densiometric analysis. Curcuminoids
inhibited the formation of 17OH-pregnenolone and DHEA in human adrenal NCI-H295R cells. A block
of DHEA production indicates that curcuminoids caused inhibition of both the 17α-hydroxylase as well
as 17,20 lyase activities of CYP17A1. Ethanol and dimethyl sulfoxide (DMSO) were used as controls at
0.1% of the total reaction volume.
2.4. Bioactivity of Curcuminoids on CYP17A1
After we saw the prel minary results indicating a block of DHEA production by curcuminoids
that were similar to inhibition caused by abiraterone, we did further experiments to check the details
of steroid biosynthesis inhibition by curcuminoids. We tested the effect of different concentrations of
curcuminoids on the 17α-hydroxylase and 17,20 lyase activities of CYP17A1 (Figure 6A). We observed
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inhibitory effects of curcuminoids on both the 17α-hydroxylase as well as 17,20 lyase activities of
CYP17A1 in a dose-dependent manner (Figure 6B,C). Abiraterone, a known inhibitor for CYP17A1,
which was used as a control, also inhibited the CYP17A1 activities. Overall, inhibition by curcuminoids
of the CYP17A1 17,20 lyase activity seemed stronger compared to the inhibition of the 17α-hydroxylase
activity (Figure 6C). A stronger inhibition of 17,20 lyase activity may be due to direct competition with
17OH-pregnenolone or blocking the interaction of CYP17A1 with cytochrome b5 [56].
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Figure 6. Inhibitory effects of curcuminoids (CCM) on CYP17A1 activities. Abiraterone, a known 
inhibitor for CYP17A1, was used as a control. Human adrenal NCI-H295R cells were treated with 
different concentrations of the curcuminoid preparation extracted from turmeric. The CYP17A1 
converts pregnenolone into 17α-hydroxypregnenolone by its 17α-hydroxylase activity, and 17α-
hydroxypregnenolone is converted into DHEA by the 17,20 lyase activity of CYP17A1. Each 
experiment was done in triplicate. The final volume of ethanol in experiments was 0.1%, and trilostane 
(at 1 µM concentration) was used to block the activity of HSD3B2, which converts pregnenolone into 
progesterone. First a pilot experiment was performed to test the effect of curcuminoids (A), and then 
several different concentrations of curcuminoids were used to determine the inhibition of CYP17A1 
activities by curcuminoids (B, C). (A) Inhibition of CYP17A1 17α-hydroxylase activity at a 
curcuminoid (CCM) concentration of 10 µg/ml, and inhibition of CYP17A1 17,20 lyase activity at a 
curcuminoid concentration of 10 µg/ml. (B) Differential inhibition of curcuminoids on CYP17A1 17α-
hydroxylase activity. (C) Differential inhibition of curcuminoids on CYP17A1 17,20 lyase activity. 
Data are presented as the mean and standard deviation (error bars) of three independent replicates 
with *p < 0.05; **p < 0.001 considered significant. One-way ANOVA was performed between each 
sample with its own ethanol control to confirm the CYP17A1 inhibition by curcuminoids. 
2.4. Bioactivity of Curcuminoids on CYP21A2 
We used 17-hydroxyprogesterone as a substrate for CYP21A2 activity and monitored the 
production of 11-deoxycortisol to quantify the effect of curcuminoids. Human adrenal NCI-H295R 
cells do not use 17-hydroxyprogesterone as a substrate of CYP17A1 and therefore, are a good model 
for assay of CYP21A2 activities using 17-hydroxyprogesterone. We tested the bioactivity of 
i r . Inhibitory effects of curcu inoi s ( ) cti ities. Abirater e, a
inhibitor for CYP17A1, was used as a control. Human adrenal NCI-H295R cells were treated with different
concentrations of the curcuminoid preparation extracted from turmeric. The CYP17A1 converts pregnenolone
into 17α-hydroxypregnenolone by its 17α-hydroxylase activity, and 17α-hydroxypregnenolone is converted
into DHEA by the 17,20 lyase activity of CYP17A1. Each experiment was done in triplicate. The final
volume of ethanol in experiments was 0.1%, and trilostane (at 1 µM concentration) was used to block
the activity of HSD3B2, which converts pregnenolone into progesterone. First a pilot experiment
was performed to test the effect of curcuminoids (A), and then several different concentrations
of curcuminoids were used to determine the inhibition of CYP17A1 activities by curcuminoids
(B,C). (A) Inhibition of CYP17A1 17α-hydroxylase activity at a curcuminoid (CCM) concentration of
10 µg/mL, and inhibition of CYP17A1 17,20 lyase activity at a curcuminoid concentration of 10 µg/mL.
(B) Differential inhibition of curcuminoids on CYP17A1 17α-hydroxylase activity. (C) Differential
inhibition of curcuminoids on CYP17A1 17,20 lyase activity. Data are presented as the mean and
standard deviation (error bars) of three independent replicates with * p < 0.05; ** p < 0.001 considered
significant. One-way ANOVA was performed between each sample with its own ethanol control to
confirm the CYP17A1 inhibition by curcuminoids.
2.5. Bioactivity of Curcuminoids on CYP21A2
We used 17-hydroxyprogesterone as a substrate for CYP21A2 activity and monitored the
production of 11-deoxycortisol to quantify the effect of curcuminoids. Human adrenal NCI-H295R
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cells do not use 17-hydroxyprogesterone as a substrate of CYP17A1 and therefore, are a good model for
assay of CYP21A2 activities using 17-hydroxyprogesterone. We tested the bioactivity of curcuminoids
at 5 µg/mL and 10 µg/mL concentrations for effect on CYP21A2 activity (Figure 7). At 10 µg/mL
concentration of curcuminoids the reduction in activity of CYP21A2 was not found to be significant
compared to the control and was less than the effects observed for inhibition of CYP171 and CYP19A1
activities. The anti-prostate cancer drug abiraterone inhibited CYP21A2 activity as we have shown
previously [40,41].
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Figure 7. Effect of curcuminoids on CYP21A2 activity. Bioactivity of curcuminoids on CYP21A2 was
measured at two different concentrations. Human adrenal NCI-H295R cells were used as a source
of CYP21A2 activity. In human adrenals, CYP17A1 does not utilize 17α-hydroxyprogesterone as
a substrate, and therefore, for the assay of CYP21A2 activity, 17α-hydroxyprogesterone was used as
a substrate and reaction was monitored by measuring the production of 11-deoxycortisol. NCI-H295R
cells were seeded overnight and then incubated with curcuminoids. After the incubations, [3H]-17α-OH
progesterone was added to the medium as the substrate. Following the reactions, steroids were extracted
by organic solvents, dried under nitrogen and separated by TLC. Production of 11-deoxycortisol from
17α-OH progesterone was measured by autoradiographic analysis of steroids on TLC plates as described
in methods. The reduction in activity of CYP21A2 observed was not statistically significant at 10 µg/mL
of curcuminoids. Ethanol concentration was 0.1% in the control reaction and abiraterone (Abi), a known
inhibitor of CYP21A2, was used as a positive control. Data shown here are from the mean and standard
deviation (error bars) of three independent experiments. One-way ANOVA was used as a statistical
method to compare each sample with the control giving significant results when ** p < 0.001.
2.6. Bioactivity of Curcumi oids on CYP19A1
To test the effect of curcuminoids on the aromatase activity of CYP19A1, we used androstenedione
as substrate and monitored its metabolism by quantifying the release of tritiated water from radiolabeled
androstenedione. A preparation of endoplasmic reticulum obtained from the placental JEG3 cells was
used for the assay of aromatase enzyme activity. A dose-response effect showing the inhibition of
aromatase with the increasing amounts of curcuminoids was seen from 0.78 to 100 µg/mL concentration
of curcuminoids (Figure 8). A known inhibitor of CYP19A1, anastrozole was used as a positive control
at 100 nM concentration and showed inhibition of CYP19A1 activity as expected.
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Figure 8. Effect of curcuminoids on CYP19A1 activity. A dose-response profile is shown indicating the
inhibition of aromatase by curcuminoids. A preparation of endoplasmic reticulum obtained from JEG3
placental cells was used as a source of aromatase activity, and tritium-labeled androstenedione was
used as a substrate. The CYP19A1 reaction was monitored by calculating the amount of tritiated water
released by CYP19A1 during the aromatization of androstenedione. A known inhibitor of CYP19A1,
anastrozole (100 nM) was used as a positive control. Curcuminoids showed a small effect on CYP19A1
activity 6.25 µg/mL and higher inhibition was observed at 12.5, 25, 50, and 100 µg/mL concentrations of
curcuminoids, indicating natural curcuminoids present in C. longa are not potent inhibitors of aromatase
activity. Data are presented as the mean and standard deviation of three independent replicates.
One-way ANOVA was used as a statistical method to compare each sample with the control (Ctrl)
giving significant results at * p < 0.05 and ** p < 0.001.
2.7. Computational Docking of Curcumin into the Human CYP17A1, CYP21A2, and CYP19A1 Crystal Structures
After observing the inhibitory effects of curcuminoids on CYP17A1, CYP19A1, and CYP21A2,
we performed computational docking of curcumin into the protein structures of these cytochromes
P450 to understand the molecular nature of inhibition. The molecular structure of curcumin resembles
steroid substrates of cytochromes P450 studied in this report, and therefore, we wanted to check
whether curcumin fits into the active site of these steroid metabolizing enzymes. Curcumin was
docked into the crystal structures of human steroid metabolizing cytochrome P450 CYP17A1, CYP19A1,
and CYP21A2 using the docking program Autodock VINA (Figure 9). Superimposition of P450
structures with either their substrates or the curcumin docked into the active site revealed similar
binding poses (Figure 9). We observed a close binding pattern from the docking of curcumin into the
active sites of CYP17A1 and CYP19A1 crystal structures (heme iron to curcumin distances < 2.5 Å)
(Figure 9). The binding pose of curcumin into CYP21A2 structure was also like its binding into the
CYP17A1 and CYP19A1 structures. A comparison of the CYP17A1 and CYP19A1 crystal structures in
complex with curcumin and docked curcumin into the crystal structure of CYP21A2 revealed similar
binding conformations, but the distance of the curcumin to the central heme iron of CYP21A2 was
longer (3.4 Å versus 2.4 Å) (Figure 9). Binding of curcumin with CYP17A1, CYP19A1, and CYP21A2
shares many similarities with the binding of steroid substrates into the active sites of these cytochrome
P450 proteins with many similar active site residues involved in binding. These results indicate that
curcumin may act as an active site inhibitor and occupy the same space in cytochrome P450 active sites
as used by their steroid substrates.
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steroid ligands were removed before docking of curcumin into the active site of P450s. The poses in 
which curcumin docks are similar to steroid substrates of all three P450s, with closer fitting in case of 
CYP17A1 (A) and CYP19A1 (B) as compared to CYP21A2 (C) (distance from heme 2.5 Å for 
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Figure 9. Docking of curcumin into the protein structures of CYP17A1 (A), CYP19A1 (B), and CYP21A2
(C). Published crystal structures of CYP17A1, CYP19A1, and CYP21A2 were used for docking of
curcumin by software AUTODOCK-VINA as described in materials and methods. Bound steroid
ligands were removed before docking of curcumin into the active site of P450s. The poses in which
curcumin docks are similar to steroid substrates of all three P450s, with closer fitting in case of CYP17A1
(A) and CYP19A1 (B) as compared to CYP21A2 (C) (distance from heme 2.5 Å for CYP17A1/CYP19A1
versus 3.4 Å for CYP21A2).
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3. Discussion
All steroid hormones are produced from cholesterol [57]. The abnormal production of steroid
hormones, for example, the hypercortisolemia seen in Cushing´s syndrome, is a life-threatening
condition [58,59]. The hyperandrogenism is not life-threatening by itself but creates many severe
complications during all phases of life. Androgens regulate sexual differentiation in both the female as
well as male and disruption of androgen biosynthesis by mutations in steroid metabolizing enzymes,
or their redox partners, cause metabolic disorders [60]. Non-tumoral cases of hyperandrogenism
include polycystic ovary syndrome (most common metabolic disorder in females), congenital adrenal
hyperplasia caused by 21-hydroxylase deficiency, and Cushing’s syndrome [61,62]. Overproduction of
cortisol and androgens could be therapeutically controlled by inhibitors that block specific steps in
steroid biosynthesis.
CYP17A1 catalyzes multiple reactions in the steroid biosynthesis pathway [63–65]. The main
activities of CYP17A1 include the 17α-hydroxylase activity needed for the biosynthesis of
17OH-pregnenolone (17OH-PREG) and 17OH-progesterone (17OH-PROG), the precursors of cortisol.
The CYP17A1 provides qualitative regulation of steroid production in humans by its 17,20 lyase activity
that produces dehydroepiandrosterone (DHEA), the precursor of sex steroids. The two distinct enzyme
activities of CYP17A1 dictate the nature of steroids synthesized in different types of cells [39,56].
Overproduction of androgens by the activation of CYP17A1-17,20 lyase activity has been linked to
polycystic ovary syndrome. CYP17A1 is also a metabolic target for chemotherapy of castration-resistant
prostate cancer [40,66].
Novel compounds that are safe and non-toxic are needed to target CYP17A1 and CYP19A1
activities to treat metabolic disorders resulting from excess production of androgens or estrogens.
Here we have probed the potential of curcuminoids as possible test candidates for synthesizing novel
chemicals to target CYP17A1 and CYP21A2. We found a dose-dependent inhibition of both CYP17A1
and CYP19A1 by curcuminoids. In our current study, curcuminoids caused a reduction of CYP21A2
activity. A reduction in CYP21A2 activity was observed at 10 µg/mL concentration of curcuminoids.
Based on these results, we can conclude that curcuminoids may cause an intricate pattern of changes
in steroid metabolites due to small to moderate inhibition of CYP19A1 and CYP21A2 activities in
addition to significant inhibition of 17α-hydroxylase as well as 17,20 lyase activity of CYP17A1.
Curcumin has been tested on the five drug-metabolizing enzymes from the cytochrome P450
family, in vivo [67] and in vitro [68,69], showing that CYP1A2, CYP2B6, CYP2C9, CYP2D6, and CYP3A4
can be inhibited by curcuminoids in a dose-dependent matter. Our studies provide an analysis of the
inhibitory effects of curcuminoids on CYP17A1 and CYP19A1 activities. These results indicate that
steroid production in people with high amounts of curcuma consumption may be affected not only by
the inhibition of CYP17A1 activities but also by the inhibition of CYP19A1 and to a smaller extent,
the inhibition of CYP21A2 enzyme activity. Also, use of curcuminoids as a common over the counter
health supplement requires further caution as inhibition of both CYP17A1 and CYP19A1 activities
may potentially result in complications of steroid metabolism in both males and females. Inhibitors of
steroidogenesis act on multiple steps in steroid biosynthesis. Many drugs have been approved for use
as steroid biosynthesis inhibitors (Ketoconazole, Metyrapone, Etomidate, Mitotane). All these drugs
inhibit CYP17A1, CYP11A1, CYP11B1, and CYP19A1 [70]. Also, many other inhibitors which can block
androgen biosynthesis in androgen-dependent prostate cancers are being studied [41,71–73]. Curcumin
in native forms as well as in nano particle preparations of curcuminoids and their analogues have
been tested for their therapeutic role in prostate cancer [25,74]. However, the effect of curcuminoids
on steroid metabolizing cytochrome P450 enzymes that play a major role in regulation of androgens
and estrogens in normal as well as cancerous tissues, has not been studied. Our results describing the
inhibitory effect of curcuminoids on CYP17A1 as well as CYP19A1 indicate that some of the effects of
curcuminoids seen in studies on prostate cancer and breast cancer cell lines, may be due to inhibition
of steroidogenic cytochrome P450 enzymes.
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Stability of curcuminoids has been a major concern for its direct use as it degrades rapidly
into trans-6-(4′-hydroxy-3′-methoxy phenyl)-2,4-dioxo-5-hexenal, vanillin, ferulic acid, and feruloyl
methane [75]. Some of the curcumin degradation products can have toxic side effects [76]. Bioavailability
and stability of curcumin could be improved by the use of sustained-release nanoparticles or liposome
preparations [29–33,77]. Several different approaches to prepare nanoparticle formulations of curcumin
have been used in recent years and tested in different disease models. A poly(lactic-co-glycolic acid)
(PLGA) nanoparticle preparation of curcumin was shown to have good activity in tests on prostate
cancer cell lines [25]. An important formulation has been the use of curcumin with piperine, which has
been found to enhance the bioavailability as well as effects of curcumin [78,79]. A recent study had
shown inhibition of SRD5A2 activity by curcumin and some of its synthetic analogues [80]. Synthetic
analogues of curcumin have also been shown to have antiparasitic activities against Trypanosoma
and Leishmania parasites [81]. A nanocurcumin preparation has been shown to protect against the
neurodegenerative effects from cerebral malaria in a mouse model [32]. There is good indication
from work on nano particle-based curcumin and its synthetic analogues that bioavailability as well as
stability of curcuminoids could be improved. In addition to prostate cancer cell models, curcumin
nano particle formulations have been used in many different conditions with improved efficacy and
are considered safe for human consumption [82–84]. However, most information about substances like
curcumin which are known from traditional medicine is based on herbal formulations and purified
active ingredients and their synthetic analogues need validation [85].
4. Materials and Methods
4.1. Materials
Radiolabeled [3H]-pregnenolone, [7(N)-3H]-pregnenolone (12.6 Ci/mmol), and [3H]-androstenedione:
Andros-4-ene-3, 17-dione, [1β-3H(N)]-, 250 µCi (9.25 MBq) were purchased from PerkinElmer (Waltham,
MA, USA). [3H]-17α-OH progesterone [1, 2, 6, 7-3H] (60-120 Ci/mmol 2.22-4.44 TBq/mmol) was obtained
from American Radiolabeled Chemicals Inc. (St. Louis, MO, USA). Silica gel-coated aluminum backed
TLC plates were purchased from Macherey-Nagel (Oensingen, Switzerland). The tritium-screens
used for the autoradiography were purchased from Fujifilm (Dielsdorf, Switzerland). Turmeric
extract capsules (from Curcuma longa) were obtained from the Finest Natural (Item: 943.17, Deerfield,
IL, USA). Trilostane was extracted in absolute ethanol (EtOH) from tablets commercially available as
Modrenal® (Bioenvision, NY, USA). Abiraterone was purchased from Selleckchem (Houston, TX, USA).
Anastrozole was obtained from AstraZeneca (Cambridge, UK).
4.2. Cell Lines and Culture Media
Human placental JEG3 cells [86] were purchased from American Type Culture Collection (ATCC)
(ATCC: HTB-36™) and cultured in minimal essential medium (MEM) with Earle’s salts (Thermo Fisher
Scientific, Waltham, MA, USA) supplemented with 10% fetal bovine serum, 1% L-glutamine (200 mM
GIBCO), 1% penicillin (100 U/ml; GIBCO), and streptomycin (100 µg/mL; (Thermo Fisher Scientific,
Waltham, MA, USA)). Human adrenocortical NCI-H295R (NCI-H295R) cells [53,87,88] were purchased
from ATCC (ATCC: CRL-2128) and grown in DMEM/Ham’s F-12 medium containing L-glutamine and
15 mM HEPES ((Thermo Fisher Scientific, Waltham, MA, USA)) supplemented with 5% NU-I serum
(Becton Dickinson, Franklin Lakes, NJ USA), 0.1% insulin, transferrin, selenium (100 U/mL; (Thermo
Fisher Scientific, Waltham, MA, USA)), 1% penicillin (100 U/mL; (Thermo Fisher Scientific, Waltham,
MA, USA), and streptomycin (100 µg/mL; GIBCO) and passage numbers during the experiments
remained below 30 according to established protocols [40,41,55,56,89,90]. Human embryonic kidney
HEK293 cells (ATCC: CRL-1573) [91] were grown in DMEM GlutaMAX TM medium supplemented
with 10% fetal bovine serum (FBS), 1% antibiotic mix (100 ×), and 1 mM sodium pyruvate.
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4.3. Curcuminoid Extraction and Analysis
To obtain a crude turmeric extract, we mixed 20 g of turmeric in 200 mL of ethanol and kept
it overnight. The ethanol extract was filtered and dried under nitrogen. Pure curcuminoids were
obtained by recrystallization using hexane and propanol as described previously. In brief, dried ethanol
extract powder was dissolved in hexane and centrifuged at 2000× g for 15 min, and the supernatant
was discarded. The pellet from the hexane extraction was dissolved in a propanol/hexane mixture
(50% propanol + 50% hexane). The solution was mixed for 90 min and then stored at 4 ◦C overnight
for crystallization. The next day, the soluble fraction was removed, and the crystallized curcuminoids
were dried under nitrogen. A stock solution of curcuminoid stock was made by mixing 10 mg of the
crystallized curcuminoid powder in 1 mL of 100% ethanol. The purity of the curcuminoid extract was
tested by thin-layer chromatography [92] (Figure 2). Curcuminoid extract was further analyzed by
UV–Vis and fluorescence spectroscopy to compare the spectral properties of our preparation with
previous extraction procedures.
The absorption spectra of curcumin in ethanol were collected using a microplate reader (Spectramax
M2e, Molecular Devices, Sunnyvale, CA, USA). In brief, different concentrations of curcumin
(1.25–20 µM) in ethanol were scanned within the wavelength range of 350–550 nm at 1 nm intervals
in a total volume of 200 µL. All UV–Vis measurements were performed at 25 ◦C and corrected
for the solvent medium (ethanol). Similarly, the fluorescence spectra of varying concentrations of
curcuminoids were also recorded at 25 ◦C on a microplate spectrofluorometer system (Spectramax M2e,
Molecular Devices, Sunnyvale, CA). Ethanol solutions of curcuminoids at 1.25, 2.5, 5, 10, and 20 µM
concentrations in a volume of 100 µL were scanned at 2 nm intervals. The emission spectra were
measured with an excitation wavelength set at 425 nm, and emission was scanned between 480–650 nm.
4.4. Cell Viability Assay Using 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide (MTT)
Human adrenal NCI-H295R cells were seeded in 96-well culture plates at a density of 3 × 105 cells
per well and grown overnight at 37 ◦C under 5% CO2, and 90% humidity. After 24 h, the medium
was changed, and serial dilutions of curcuminoids were added to the medium and incubation of
cells was continued for another 24 h. After the incubation of cells with curcuminoids, 20 µL of MTT
reagent (5 mg/mL in PBS) was added into each well, and the incubation was continued for another 4 h.
After the incubation with MTT reagent, culture medium was removed and 200 µL of DMSO was added
in each well, and the plate was incubated for 20 min in the dark. The absorbance in individual wells
was then measured at 570 nm, and calculations of cell viability were performed based on residual MTT
reduction activity of cells compared to controls without curcuminoids. As another control, the toxicity
of curcuminoids on human HEK-293 cells was also tested under similar conditions using the methods
described for NCI-H295R cells.
4.5. Assay of CYP17A1 and CYP21A2 Activities
Human adrenal NCI-H295R cells were seeded in 6-well tissue culture plates at a density of
1× 106 cells per well. Steroid metabolism by NCI-H295R cells has been studied in our laboratory for many
years and culture conditions and passage numbers (kept below 30) adhered to previously established
protocols [40,41,55,56,89,90]. After overnight incubation, medium was changed, and different
concentrations of curcuminoids were added to the incumation medium and incubation was continued
for 24 h. A known inhibitor of CYP17A1 and CYP21A2, abiraterone (1 µM), was used as a control for
both assays. NCI-H295R cells were treated with trilostane (1 µM), an inhibitor of HSD3B2, 90 min
before the addition of radiolabeled substrates. For CYP17A1 activity assays, ~100,000 cpm/well of
[3H]-pregnenolone was added to each well. For the determination of CYP21A2 activity, [3H]-17α-OH
progesterone (~50,000 cpm/well) was used as a substrate. After incubations with radiolabeled substrates,
medium from each well was collected, and steroids were extracted in ethyl acetate:isooctane (1:1).
Extracted steroids were concentrated under nitrogen and dissolved in 20 µL of trichloromethane
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for separation by thin-layer chromatography on silica gel thin layer chromatography (TLC) plates
(Macherey-Nagel, Oensingen, Switzerland). Radiolabeled steroids were quantified by autoradiography
on a Fuji FLA-7000 PhosphorImager (Fujifilm, Dielsdorf, Switzerland). Quantification of steroids was
done using MultiGauge software (Fujifilm, Dielsdorf, Switzerland).
4.6. Preparation of Microsomes from JEG3 Cells
JEG3 cells were collected near confluency and washed with cold PBS. The cell suspension was
then centrifuged at 1500× g for 5 min to pellet the cells. Afterward, the cell pellet was suspended in
100 mM Na3PO4 (pH 7.4) containing 150 mM KCl, and the cells were lysed by sonication. Unbroken
cells and mitochondria were pelleted by centrifugation at 14,000× g for 15 min at 4 ◦C. Microsomes
containing endoplasmic reticulum were collected by ultracentrifugation at 100,000× g for 90 min at
4 ◦C and resuspended in 50 mM K3PO4 (pH 7.4) containing 20% glycerol [56]. The protein content of
microsomes was measured by the BioRad Protein Assay Kit (BioRad, Hercules, CA, USA).
4.7. Assay of CYP19A1 Activity
The aromatase activity of CYP19A1 was measured by calculating the release of tritiated water
from the substrate during aromatization. Assays of aromatase activity were carried out using 40 µg of
microsomes from JEG3 cells in 100 mM potassium phosphate buffer (pH 7.4) containing 100 mM NaCl
in a final volume of 200 µL. Different concentrations of curcuminoids were added to reaction mixtures,
and ethanol was used as the control. A known inhibitor of CYP19A1, anastrozole was included in some
reactions as a positive control. Assays were performed using 50 nM androstenedione as a substrate
and contained ~20,000 cpm of [3H]-androstenedione as a radioactive tracer. The aromatase reaction
was initiated by the addition of reduced nicotinamide adenine dinucleotide phosphate (NADPH) to
1 mM final concentration and incubations were done at 37 ◦C with constant shaking for 1 h. Afterward,
800 µL of a solution containing 5% charcoal with 0.5% dextran was added to each reaction mixture and
mixed by vortexing followed by centrifugation at 15,000× g for 10 min. From each reaction, 500 µL
aliquots were taken for the measurement of radioactivity by scintillation counting using the Rotiszint
Universal Cocktail (Carl Roth GmbH, Karlsruhe, Germany), and aromatase activity was calculated as
described previously [93,94].
4.8. Docking of Curcumin into CYP17A1, CYP19A1, and CYP21A2 Protein Structures
The published 3D structures of human CYP17A1, CYP19A1, and CYP21A2 were obtained from
the protein data bank (PDB) database. We made in-silico calculations and structure analysis with
YASARA [95]. For docking experiments, X-ray crystal structures of human of CYP17A1 (PDB# 3RUK),
CYP19A1 (PDB# 3EQM), and CYP21A2 (PDB # 4Y8W), were used [96–98]. Missing hydrogen atoms
in the structures were added with YASARA [95], which was also used for all other calculations.
The resulting minimum energy structures were used for AutoDock VINA [99] to perform docking
experiments with curcumin (orthorhombic docking was grid established around the central heme
molecule). The final poses of curcumin were selected based on their docking location and scores,
and resemblance to the co-crystallized ligands in the P450 structures. Structure models were drawn
with Pymol (Schrödinger, New York, NY, USA)
4.9. Statistical Analysis
For the statistical analysis, Microsoft Excel and GraphPad Prism (Graph Pad Software, Inc.
San Diego, CA, USA) were used. Data are presented as the mean and standard deviation of 3 independent
replicates. One-way ANOVA was used to calculate the differences between the samples with the
corresponding controls. Significance cutoffs for experiments was set at * p < 0.05 and ** p < 0.001.
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5. Conclusions
Computational docking from our experiments showed that curcumin could bind into the active
sites of steroid metabolizing P450s. The inhibition of CYP17A1 and CYP19A1 by curcuminoids provides
a template for structure modification to produce effective and safe compounds that can target prostate
cancer as well as breast cancer. Curcumin-based compounds can be further optimized for delivery as
nano formulations, which have been tried in laboratory animals [37,100,101] as well as in human trials
and shown to be safe [29,82]. Only a minor effect on CYP21A2 activity by curcuminoids compared to
inhibition of CYP17A1 (50% inhibition of 17,20 lyase activity at 5 µg/ml compared to no significant
effect on CYP21A2 activity at the same concentration) was observed. This suggests that compounds
based on curcuminoids may be better and safer inhibitors for use in hyperandrogenic states like
polycystic ovary syndrome, especially in children and young adults, and avoid the toxic effects of
abiraterone which severely inhibits CYP21A2 activity [40,41].
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